Plasma p-tau231: a new biomarker for incipient Alzheimer’s disease pathology.
Open accessThe DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.
Abstract
The quantification of phosphorylated tau in biofluids, either cerebrospinal fluid (CSF) or plasma, has shown great promise in detecting Alzheimer’s disease (AD) pathophysiology. Tau phosphorylated at threonine 231 (p-tau231) is one such biomarker in CSF but its usefulness as a blood biomarker is currently unknown. Here, we developed an ultrasensitive Single molecule array (Simoa) for the quantification of plasma p-tau231 which was validated in four independent cohorts ( n = 588) in different settings, including the full AD continuum and non-AD neurodegenerative disorders. Plasma p-tau231 was able to identify patients with AD and differentiate them from amyloid-β negative cognitively unimpaired (CU) older adults with high accuracy (AUC = 0.92–0.94). Plasma p-tau231 also distinguished AD patients from patients with non-AD neurodegenerative disorders (AUC = 0.93), as well as from amyloid-β negative MCI patients (AUC = 0.89). In a neuropathology cohort, plasma p-tau231 in samples taken on avergae 4.2 years prior to post-mortem very accurately identified AD neuropathology in comparison to non-AD neurodegenerative disorders (AUC = 0.99), this is despite all patients being given an AD dementia diagnosis during life. Plasma p-tau231 was highly correlated with CSF p-tau231, tau pathology as assessed by [ 18 F]MK-6240 positron emission tomography (PET), and brain amyloidosis by [ 18 F]AZD469 PET. Remarkably, the inflection point of plasma p-tau231, increasing as a function of continuous [ 18 F]AZD469 amyloid-β PET standardized uptake value ratio, was shown to be earlier than standard thresholds of amyloid-β PET positivity and the increase of plasma p-tau181. Furthermore, plasma p-tau231 was significantly increased in amyloid-β PET quartiles 2–4, whereas CSF p-tau217 and plasma p-tau181 increased only at quartiles 3–4 and 4, respectively. Finally, plasma p-tau231 differentiated individuals across the entire Braak stage spectrum, including Braak staging from Braak 0 through Braak I–II, which was not observed for plasma p-tau181. To conclude, this novel plasma p-tau231 assay identifies the clinical stages of AD and neuropathology equally well as plasma p-tau181, but increases earlier, already with subtle amyloid-β deposition, prior to the threshold for amyloid-β PET positivity has been attained, and also in response to early brain tau deposition. Thus, plasma p-tau231 is a promising novel biomarker of emerging AD pathology with the potential to facilitate clinical trials to identify vulnerable populations below PET threshold of amyloid-β positivity or apparent entorhinal tau deposition.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Fig. 2 Plasma p-tau231 concentration correlates with PET and CSF tau and Aβ. The brain maps show the results of linear regressions false discovery rate corrected for multiple comparisons at P < 0.05, whereas the plots show the results of Spearman rank correlation between biomarkers. a Plasma p-tau231 concentrations were associated with [18F]MK-6240 SUVR across the cortex with the highest association in the temporal and posterior cingulate cortices as well as with b CSF p-tau231 concentrations. c Plasma p-tau231 correlates with [18F]AZD4694 SUVR across the cortex and with d CSF Aβ1-42 concentrations](https://figures.cochat.ai/paper-figures/11450d600b6547cd8ddd582223ba6f57/plasma-p-tau231-a-new-biomarker-for-incipient-alzheimers-disease-pathology-figure-2.jpg)



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Among proposed blood tau biomarkers,18,19,20,21 phosphorylated tau at threonine 217 (p-tau217) has consistently shown high performance in differentiating AD from other neurodegenerative disorders10,22 and in detecting AD pathology in patients with mild cognitive impairment (MCI).22”
From Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease Pathology (2024) · cites this paper as [18]
The cited source says what the claim attributes to it.
In the citing paper
“The new plasma p-tau231 Simoa assay has been previously described and validated2.”
From Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer’s disease (2022) · cites this paper as [2]
The cited source says what the claim attributes to it.
In the citing paper
“Plasma measures of phosphorylated tau at Thr181 (p-tau181), Thr217 (p-tau217) and Thr231 (p-tau231) have high diagnostic accuracy in differentiating AD from other neurodegenerative disorders in clinical studies1–3, which are validated by postmortem neuropathological studies1,2,4.”
From Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer’s disease (2022) · cites this paper as [2]
The cited source says what the claim attributes to it.
In the citing paper
“Subsequently, the first blood analysis of p-tau231 (ref. 2) demonstrated earlier increases than plasma p-tau181 in a small set of participants.”
From Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer’s disease (2022) · cites this paper as [2]
The cited source says what the claim attributes to it.
In the citing paper
“P-tau231 levels in blood have also recently been demonstrated to increase earlier than p-tau18160 (Tissot et al., 2022), however, a direct comparison with p-tau217 in early preclinical disease is not currently available.”
From Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer's disease (2022) · cites this paper as [60]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
Robust Locally Weighted Regression and Smoothing Scatterplots
Cleveland, W. S. (1979) · Journal of the American Statistical Association · doi:10.1080/01621459.1979.10481038 · Cited by 11,594
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537
Self-citationClinical and biomarker changes in dominantly inherited Alzheimer's disease
Bateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., Marcus, D. S., Cairns, N. J., Xie, X., Blazey, T. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202753 · Cited by 3,814
Braak, H., Alafuzoff, I., Arzberger, T., Kretzschmar, H., & Del Tredici, K. (2006) · Acta Neuropathologica · doi:10.1007/s00401-006-0127-z · Cited by 3,172
Olsson, B., Lautner, R., Andreasson, U., Öhrfelt, A., Portelius, E., Bjerke, M., Hölttä, M., Rosén, C., Olsson, C., Strobel, G., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)00070-3 · Cited by 2,049
Self-citationHigh performance plasma amyloid-β biomarkers for Alzheimer's disease
Nakamura, A., Kaneko, N., Villemagne, V. L., Kato, T., Doecke, J., Doré, V., Fowler, C., Li, Q.-X., Martins, R., Rowe, C., et al. (2018) · Nature · doi:10.1038/nature25456 · Cited by 1,681
Palmqvist, S., Janelidze, S., Quiroz, Y. T., Zetterberg, H., Lopera, F., Stomrud, E., Su, Y., Chen, Y., Serrano, G. E., Leuzy, A., et al. (2020) · JAMA · doi:10.1001/jama.2020.12134 · Cited by 1,603
Self-citationThe Centiloid Project: standardizing quantitative amyloid plaque estimation by PET
Klunk, W. E., Koeppe, R. A., Price, J. C., Benzinger, T. L., Devous, M. D., Jagust, W. J., Johnson, K. A., Mathis, C. A., Minhas, D., Pontecorvo, M. J., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.07.003 · Cited by 1,348
Cited by
Items 601–700 of 769
Performance of plasma amyloid, tau, and astrocyte biomarkers to identify cerebral AD pathophysiologyPreprint
Ferreira, P. C. L., Tissot, C., Ferrari‐Souza, J. P., Brum, W. S., Bellaver, B., Leffa, D. T., Therriault, J., Benedet, A. L., Lussier, F. Z., Chamoun, M., et al. (2022) · medRxiv · doi:10.1101/2022.02.21.22271198
Self-citationMontoliu‐Gaya, L., Alcolea, D. A., Ashton, N. J., Pegueroles, J., Levin, J., Carmona‐Iragui, M., Lantero‐Rodriguez, J., Karikari, T. K., Barroeta, I., Kac, P. R., et al. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4077901
Self-citationNielsen, J. E. (2021) · VBN Forskningsportal (Aalborg Universitet) · doi:10.54337/aau455017331
Reducing unnecessary tau-PET scans in a memory clinic setting via blood-based biomarker screeningPreprint
Cullen, N. C., Janelidze, S., Stomrud, E., Palmqvist, S., Braum, W., Zetterberg, H., Frisoni, G. B., Ashton, N. J., Blennow, K., Mattsson, N., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1818516/v1
Self-citationBiomarkers in cerebrospinal fluid and blood aid diagnosis of dementia
Rosenberg, G. A. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-823455-6.00001-8
Imaging early brain characteristics of alzheimer’s disease: Structure, function and symptomatology
van Hooren, R. W. E. (2022) · Research Publications (Maastricht University) · doi:10.26481/dis.20221215rh
Research and Prospect of Blood Biomarkers for Alzheimer’s Disease
蓝, 萍. (2023) · Hans Journal of Biomedicine · doi:10.12677/hjbm.2023.131002
The potential of extracellular vesicle lipid profiling in Alzheimer's disease.Preprint
Su, H., Masters, C. L., Bush, A. I., Barnham, K. J., Reid, G. E., & Vella, L. J. (2023) · Authorea · doi:10.22541/au.168388562.25020996/v1
A meta-analysis of progress in liquid biomarker-based diagnostic studies of Alzheimer's disease
Liu, H. (2024) · International Conference on Biological Engineering and Medical Science (ICBioMed) · doi:10.1117/12.3012991
The Role of Design Thinking in Driving Brand Innovation and Sustainable Competitive Advantage
Wunjoulane, O. (2023) · Journal of Asian Multicultural Research for Economy and Management Study · doi:10.47616/jamrems.v4i4.453
STUDY ON BLOOD PROTEIN MARKERS OF ALZHEIMER’S DISEASE
Gonon, F. (2024) · World Journal of Biomedical Sciences · doi:10.61784/wjbs240145
Vésicules extracellulaires : actrices de la propagation de la pathologie tau dans les tauopathies
Leroux, É. (2021) · theses.fr (ABES) · doi:10.70675/3318b243z20aez4b6bzace8zda153701cc2b
Paradigm Shift in AD Diagnostic Criteria: Applications and Challenges
张, 春. (2024) · Advances in Clinical Medicine · doi:10.12677/acm.2024.1482186
Clinical Assessment of a Plasma AT(N) Panel for Alzheimer’s DiseasePreprint
Collier, B. B., Chappell, M. R., Brandon, W. C., Le, T. V., Harris, A. B., Volpe, J. M., Martone, R. L., Winslow, J. W., Boles, D., Valcour, A., et al. (2024) · medRxiv · doi:10.1101/2024.08.06.24310938
USING BLOOD BIOMARKERS TO PREDICT PRECLINICAL ALZHEIMER’S DISEASE
Leclerc, H. (2024) · Digital Commons - URI (University of Rhode Island) · doi:10.23860/thesis-2485
Bogner, C. (2025) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-10978
Conectividad funcional dinámica en Alzheimer: diagnóstico temprano y evolución en el tiempo
Carrasco-Gómez, M. (2024) · UPM Digital Archive (Technical University of Madrid) · doi:10.20868/upm.thesis.84766
Luo, H., Zhang, L., Yang, C., Du, X., Gong, H., Han, Y., & Luo, Q. (2025) · Research Square · doi:10.21203/rs.3.rs-5132416/v1
Marqueurs biologiques des maladies neurodégénératives
Vrillon, A., Aveneau, C., & Paquet, C. (2025) · Encyclopédie médico-chirurgicale. Neurologie · doi:10.1016/s0246-0378(25)48607-2
Fluid and Imaging Markers of Amyloid Pathology
West, T., Meyer, M. R., Kirmess, K. M., Yarasheski, K. E., Braunstein, J. B., & Verghese, P. B. (2025) · Springer eBooks · doi:10.1007/978-3-031-80849-4_1
Dauer, M. (2025) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-11427
Blood-based immunophenotyping of T cell profiles in patients with neurodegenerative disorders
Malichova, F., Swann, P., Kigar, S. L., Yarkoni, N. S., Goddard, J., Lai, K. O., Chouliaras, L., Surendranathan, A., Turner, L., Savulich, G., et al. (2026) · Alzheimer s Research & Therapy · doi:10.1186/s13195-026-02144-y
Self-citationCharacteristics of Study Design and Statistical Analysis in OCT-Based Studies of Neurodegeneration
Caplash, S., Song, H., Waldman, A. T., Ying, G., & Kim, B. J. (2025) · Ophthalmology Science · doi:10.1016/j.xops.2025.100961
Soleimani‐Meigooni, D. N., & Rabinovici, G. D. (2025) · Cambridge University Press eBooks · doi:10.1017/9781108985055.006
Arastoo, M., Penny, L. K., Lofthouse, R. A., Hitchcock, A., Moelders, A., Szalma, S., Porter, A. J., Palliyil, S., Harrington, C. R., & Wischik, C. M. (2025) · Scientific Reports · doi:10.1038/s41598-025-25864-x
Blasco‐Forniés, H., Torres‐Torronteras, J., González‐Escalante, A., Anastasi, F., Jiménez‐Moyano, E., Ortiz‐Romero, P., Diego‐Osaba, M. D., Minguillón, C., Suárez‐Calvet, M., & del Campo, M. (2025) · Research Square · doi:10.21203/rs.3.rs-8107685/v1
Neurodiagnostic: Advances in diagnostic tools
Dave, S., Banerjee, J., Banerjee, S., & Tiwari, A. K. (2025) · International review of cytology · doi:10.1016/bs.ircmb.2025.12.001
Groot, C., Cicognola, C., Bali, D., Triana‐Baltzer, G., Dage, J. L., Pontecorvo, M. J., Kolb, H. C., Osssenkoppele, R., Janelidze, S., & Hansson, O. (2022) · Figshare · doi:10.6084/m9.figshare.19767974
Egroo, M. V., van Hooren, R. W. E., & Jacobs, H. I. L. (2021) · Figshare · doi:10.6084/m9.figshare.16680108
Martínez‐Dubarbie, F., Guerra-Ruiz, A., López‐García, S., Lage, C., Fernández‐Matarrubia, M., Infante, J., Pozueta‐Cantudo, A., García-Martínez, M., Corrales‐Pardo, A., Bravo, M., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26621608
Mazo, C. (2024) · Deep Blue (University of Michigan) · doi:10.7302/23782
Wilson, E. N., Young, C. B., Benitez, J. A. R., Swarovski, M. S., Feinstein, I., Vandijck, M. L. J., Guen, Y. L., Kasireddy, N. M., Shahid, M., Corso, N. K., et al. (2022) · Figshare · doi:10.6084/m9.figshare.21547387
Wilson, E. N., Young, C. B., Benitez, J. A. R., Swarovski, M. S., Feinstein, I., Vandijck, M. L. J., Guen, Y. L., Kasireddy, N. M., Shahid, M., Corso, N. K., et al. (2022) · Figshare · doi:10.6084/m9.figshare.21547393
Lu, J., Ma, X., Zhang, H., Xiao, Z., Li, M., Wu, J., Ju, Z., Chen, L., Zheng, L., Ge, J., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26600593
Murray, M. E., Moloney, C. M., Kouri, N., Syrjanen, J. A., Matchett, B. J., Rothberg, D. M., Tranovich, J. F., Sirmans, T. N. H., Wiste, H. J., Boon, B. D. C., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26557766
Wilson, E. N., Young, C. B., Benitez, J. A. R., Swarovski, M. S., Feinstein, I., Vandijck, M. L. J., Guen, Y. L., Kasireddy, N. M., Shahid, M., Corso, N. K., et al. (2022) · Figshare · doi:10.6084/m9.figshare.21547396
Wilson, E. N., Young, C. B., Benitez, J. A. R., Swarovski, M. S., Feinstein, I., Vandijck, M. L. J., Guen, Y. L., Kasireddy, N. M., Shahid, M., Corso, N. K., et al. (2022) · Figshare · doi:10.6084/m9.figshare.21547390
Additional file 1 of The dynamics of plasma biomarkers across the Alzheimer’s continuum
Guo, Y., Shen, X.-N., Wang, H.-F., Chen, S.-D., Zhang, Y.-R., Chen, S., Cui, M., Cheng, W., Dong, Q., Ma, T., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26567207
Wang, X., Zhang, X., Liu, J., Zhang, J., Liu, C., Cui, Y., Song, Q., Hou, Y., Wang, Y., Zhang, Q., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25599864
Guo, T., Li, A., Sun, P., He, Z., Cai, Y., Lan, G., Liu, L., Li, J., Yang, J., Zhu, Y., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26410059
Bernick, C. B., Shan, G., Ritter, A., Ashton, N. J., Blennow, K., Lantero‐Rodriguez, J., Snellman, A., & Zetterberg, H. (2024) · Figshare · doi:10.6084/m9.figshare.26626312
Self-citationAltomare, D., Libri, I., Alberici, A., Rivolta, J., Padovani, A., Ashton, N. J., Zetterberg, H., Blennow, K., & Borroni, B. (2024) · Figshare · doi:10.6084/m9.figshare.25802834
Self-citationLantero‐Rodriguez, J., Vrillon, A., Fernández‐Lebrero, A., Ortiz‐Romero, P., Snellman, A., Montoliu‐Gaya, L., Brum, W. S., Cognat, E., Dumurgier, J., Puig‐Pijoan, A., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22625720
Self-citationGuo, T., Li, A., Sun, P., He, Z., Cai, Y., Lan, G., Liu, L., Li, J., Yang, J., Zhu, Y., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26409831
Benedet, A. L., Brum, W. S., Hansson, O., Karikari, T. K., Zimmer, E. R., Zetterberg, H., Blennow, K., & Ashton, N. J. (2022) · Figshare · doi:10.6084/m9.figshare.19135820
Self-citationMundada, N. S., Rojas, J. C., Vandevrede, L., Thijssen, E. H., Iaccarino, L., Okoye, O., Shankar, R. P., Soleimani-Meigooni, D. N., Lago, A. L., Miller, B. L., et al. (2023) · Figshare · doi:10.6084/m9.figshare.24186176
Bernick, C. B., Shan, G., Ritter, A., Ashton, N. J., Blennow, K., Lantero‐Rodriguez, J., Snellman, A., & Zetterberg, H. (2024) · Figshare · doi:10.6084/m9.figshare.26626315
Self-citationWilson, E. N., Young, C. B., Benitez, J. A. R., Swarovski, M. S., Feinstein, I., Vandijck, M. L. J., Guen, Y. L., Kasireddy, N. M., Shahid, M., Corso, N. K., et al. (2022) · Figshare · doi:10.6084/m9.figshare.21547384
Li, L.-J., Sun, X.-Y., Huang, Y., Lu, S., Xu, Y.-M., Yang, J., Xie, X.-X., Zhu, J., Niu, X.-Y., Wang, D., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26488356
Memory precision across space and time in Alzheimer's disease
Toniolo, S. (2023) · Oxford University Research Archive (ORA) (University of Oxford) · doi:10.5287/ora-pzz6prj4e
Bayoumy, S., Verberk, I. M. W., den Dulk, B., Hussainali, Z., Zwan, M. D., van der Flier, W. M., Ashton, N. J., Zetterberg, H., Blennow, K., Vanbrabant, J., et al. (2021) · Figshare · doi:10.6084/m9.figshare.17126153
Self-citationVrillon, A., Mouton‐Liger, F., Martinet, M., Cognat, E., Hourrègue, C., Dumurgier, J., Bouaziz-Amar, É., Brinkmalm, A., Blennow, K., Zetterberg, H., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19845670
Self-citationPascual‐Lucas, M., Allué, J. A., Sarasa, L., Fandos, N., Castillo, S., Terencio, J. V., Sarasa, M., Tartari, J. P., Sanabria, Á., Tárraga, L., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22612958
Gobom, J., Benedet, A. L., Mattsson, N., Montoliu‐Gaya, L., Schultz, N., Ashton, N. J., Janelidze, S., Servaes, S., Sauer, M., Pascoal, T. A., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26553350
Self-citationDolado, A. O., Stomrud, E., Ashton, N. J., Nilsson, J., Quijano‐Rubio, C., Jethwa, A., Brum, W. S., Brinkmalm Westman, A., Zetterberg, H., Blennow, K., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26737833
Self-citationPuig‐Pijoan, A. (2024) · Tesis Doctorals en Xarxa (Consorci de Serveis Universitaris de Catalunya)
Emeršič, A. (2024) · Repository of the University of Ljubljana (University of Ljubljana)
Characterization of preclinical transgenic rat models for Alzheimer’s disease-like pathology
Emmerson, J. T. (2023) · eScholarship@McGill (McGill) · doi:10.82308/166
Pereira Priego, C. (2023) · RECERCAT (Consorci de Serveis Universitaris de Catalunya)
Gonzales, S. A. (2025) · ThinkIR: The University of Louisville's Institutional Repository (University of Louisville)
Cognitieve hersencircuits en de verspreiding van amyloid en tau in vivo bij mensen
Reinartz, M. (2023) · Lirias (KU Leuven)
Estudio prospectivo longitudinal en sujetos portadores del alelo 4 de la APOE.
Pinheiro Nepomuceno, M. (2023) · Repository of Digital Objects for Teaching Research and Culture (University of Valencia)
Baudin, S., Fjellström, H., Kraft, A., Lamberg, E., Rosenbaum, M., & Sjöstrand, H. (2023) · Uppsala University Publications (Uppsala University)
Vivek, S. (2023) · University of Minnesota Digital Conservancy (University of Minnesota)
Oliveira, A. C. (2023) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · doi:10.34626/gr6r-ka67
Marcatori biologici delle malattie neurodegenerative
Vrillon, A., Aveneau, C., & Paquet, C. (2025) · EMC - Neurologia · doi:10.1016/s1634-7072(25)51074-7
BIOLOGICAL FLUID BIOMARKERS FOR ALZHEIMER’S DISEASE: A NARRATIVE REVIEW
Boubga, T., Taous, A., Boulahri, T., & Berri, M. A. (2025) · MedPeer publisher · doi:10.70780/medpeer.000qgq7
Nakano, M., Kondo, K., Ishiki, K., Moniruzzaman, M., Mitsuishi, Y., KADOTA, A., Watanabe, S., Yamashita, K., Miura, M., Iwanaga, S., et al. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251409337
Blood-based emerging biomarkers in early detection and diagnosis of Alzheimer’s disease
Anand, T., & Kumar, A. (2026) · International review of neurobiology · doi:10.1016/bs.irn.2026.01.002
Wang, S., Li, Z., Funahashi, S., Zhang, Z., Wu, J., & Yang, J. (2025) · International Conference on Health Big Data and Intelligent Healthcare (ICHIH) · doi:10.1145/3792746.3792750
Verma, M., Raikwar, S., Beohar, M., Vishwakarma, N., & Sil, A. J. (2026) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9798898814021126010004
Vasilevskaya, A. (2024) · TSpace (University of Toronto)
Driscoll, I. F., Wilson, R. E., Johnson, S. C., Asthana, S., Gallagher, C. L., Hermann, B. P., Sager, M. A., Carlsson, C. M., Blennow, K., Zetterberg, H., et al. (2026) · Journal of Alzheimer s Disease · doi:10.1177/13872877261422411
Self-citationKoenig, L. N., Huber, H., Chongtham, A., Molfetta, G. D., Andrews, R. D., Lukic, A., Shafiian, N., Fillit, H. M., Blennow, K., Ashton, N. J., et al. (2026) · Brain Communications · doi:10.1093/braincomms/fcag074
Self-citationPriya, Mittal, R., Banerjee, J., & Dixit, A. B. (2026) · International review of neurobiology · doi:10.1016/bs.irn.2026.02.006
Zhang, J.-W., Li, R., Niu, Y.-X., Liu, S., Li, C.-H., Hao, X., Wang, S., Chen, S., & Wang, F. (2026) · Alzheimer s Research & Therapy · doi:10.1186/s13195-026-02016-5
Tau-proteiinin mittaaminen verestä neurodegeneratiivisissa sairauksissa
Pääkkö, J. (2026) · UTUPub (University of Turku)
Neuropathological measures of increased tau phosphorylation across the Down syndrome lifespan
Pascual, J. R., Rivera, I., Nguyen, H., Ngo, P. T., Hoang, A., Andrews, E. J., Rouanet, J. P., Wright, S. T., Sordo, L., Kofler, J. K., et al. (2026) · Acta Neuropathologica · doi:10.1007/s00401-026-02994-8
Devi, P. R., Rani, A., & Navya, D. (2026) · International Journal of Pharmacology and Clinical Research · doi:10.33545/26647613.2026.v8.i2a.187
Castelot, R. (2024) · theses.fr (ABES) · doi:10.70675/c2a7ce1ez8caaz4593zbb3azae8add8055b5
Van, K. T. (2025) · theses.fr (ABES) · doi:10.70675/32a1a6cez5dd3z42c0za2eaz2e57807081a6
Blood-based biomarkers and 20-year risk of clinically diagnosed Alzheimer’s diseasePreprint
Littlejohns, T. J., Liu, W., Maronga, C., Tong, T. Y. N., Amin, N., Breeur, M., Collister, J. A., Parsaeian, M., Papier, K., Piazza, P., et al. (2026) · medRxiv · doi:10.64898/2026.04.16.26350847
Poisnel, G., Lhérault, M., Palix, C., Turpin, A., Felisatti, F., Vrillon, A., Paquet, C., Chocat, A., Coulbault, L., Sayette, V. D. L., et al. (2026) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.70248
Neri, L. (2026) · Florence Research (University of Florence)
Tarapore, P. E., Cutone-Dion, M. J., Lombardi, D. H., Kuang, K., Lang, Y. R., Yaffe, K. S., Manley, G. T., Mukherjee, P., Gardner, R. C., & the TRACK-TBI Investigators (2026) · Neurotrauma Reports · doi:10.1177/2689288x261442468
Shabi, A. (2026) · International journal of high school research · doi:10.36838/ijhsr87.80
Chen, F., Zhang, H., Huang, Y., Zhu, J., Cui, F., Liang, S., Li, Y., Wang, Y., Xie, X., & Liu, R. (2026) · Acta Biochimica et Biophysica Sinica · doi:10.3724/abbs.2026085
Cela, E., Nynatten, L. R. V., Tweddell, D., Daley, M., Morello, M., Cepinskas, G., & Fraser, D. D. (2026) · Molecular Medicine · doi:10.1186/s10020-026-01501-9
Characterization of a distinct form of vimentin in the neurodegenerative brain
Dakhel, A., Vestin, J., Giedraitis, V., Nyholm, D., Ingelsson, M., & Erlandsson, A. (2026) · Acta Neuropathologica Communications · doi:10.1186/s40478-026-02324-9
Rana, D., Das, S., & Mazumder, A. (2026) · International Journal of Drug Delivery Technology · doi:10.25258/ijddt.16.32s.74
Current Perspectives on Alzheimer’s Disease: Biomarkers, Drug Development and Future Directions
Shrivastav, A., o'g'li, E. J. G., Rout, A., Sharma, N., Sharma, M., & Boruah, P. (2026) · International Journal of Drug Delivery Technology · doi:10.25258/ijddt.16.34s.8
Plasma p‐tau markers, vascular factors, and cognitive decline in the CIMA‐Q cohort
Cottez, R. J., Peyrot, C., Denis, H. L., Tremblay, C., Loiselle, A., Dallaire‐Théroux, C., Filali‐Mouhim, A., Hébert, S. S., Leclerc, N. M., Blennow, K., et al. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71588
Self-citationInvestigating AD and non-AD [18F]flortaucipir distribution patterns in a memory clinic cohort
Piva, F., Boccalini, C., Ashton, N. J., Zetterberg, H., Blennow, K., Frisoni, G. B., Veronese, M., Garibotto, V., & Peretti, D. E. (2026) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-026-07995-z
Self-citationGomar, J. J., Gordon, M. L., Christen, E., Giliberto, L., Keehlisen, L., Gong, M., Hoehn, N., Morley, E., O'Neil, A., Wuelfing, D. L., et al. (2026) · medRxiv · doi:10.64898/2026.06.18.26355956
Multifactorial Pathogenesis, Diagnosis, and Therapeutic Strategies in Alzheimer’s Disease
Lin, Y. (2026) · MedScien · doi:10.61173/42726n83
Tau368 improves p-tau diagnostic accuracy for FTLD-tau from FTLD-TDP
Kac, P. R., Cousins, K. A. Q., Szadziewska, A., Shaw, L. M. J., Turton, M., Deerlin, V. M. V., Harrison, P., Zetterberg, H., Wolk, D. A., McMillan, C. T., et al. (2026) · Acta Neuropathologica · doi:10.1007/s00401-026-03042-1
Self-citationFernández-Ceballos, M. D. L. Á., Prieto-González, J. M., & Agís‐Balboa, R. C. (2026) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-026-01752-4
Napolitano, L. (2026) · Firenze University Press eBooks · doi:10.36253/979-12-215-0993-9.05
Metadata
- Authors
- Ashton, N. J., Pascoal, T. A., Karikari, T. K., Benedet, A. L., Lantero-Rodriguez, J., Brinkmalm, G., Snellman, A., Schöll, M., Troakes, C., Hye, A., Gauthier, S., Vanmechelen, E., Zetterberg, H., Rosa-Neto, P., & Blennow, K.
- Affiliations
- King's College London (GB)
- University of Pittsburgh (US)
- University of Gothenburg (SE)
- McGill University (CA)
- National Hospital for Neurology and Neurosurgery (GB)
- McGill University Research Centre for Studies in Aging (CA)
- ADx NeuroSciences (BE)
- Sahlgrenska University Hospital (SE)
- Corresponding author
- Ashton, Nicholas J.
- Blennow, Kaj
- ORCID
- Venue
- Acta Neuropathologica
- Published
- 2021-02-14
- Volume
- 141
- Issue
- 5
- Pages
- 709-724
- ISSN
- 0001-6322 (ISSN-L)
- 1432-0533
- PMC
- PMC8043944
- OpenAlex
- W3131174931
- Cited by
- 719
- References
- 66
- Citations by year
- 2026: 122 · 2025: 165 · 2024: 148 · 2023: 112 · 2022: 126 · 2021: 46
- FWCI
- 77.42
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Acta Neuropathologica (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Research Portal (King's College London) (submittedVersion, other-oa)
- Funders
- University of Gothenburg
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Clinical Neurology › Cerebrospinal fluid and hydrocephalus
- Keywords
- Alzheimer's disease, tau phosphorylation, blood biomarkers, Simoa, amyloid PET, Braak staging, cognitive impairment, mild cognitive impairment, cerebrospinal fluid biomarkers, neurodegeneration, early detection of Alzheimer's disease, [18F]MK-6240
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Female, Humans, Male, Middle Aged, Phosphorylation, Biomarkers, tau Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.